Medical devices

New EU Directive on Whistleblower Protection will also apply to Life Sciences sector

Inge Vanderreken

On 7 October 2019, the Council of Ministers adopted the Directive on Whistleblower protection at the Justice and Home Affairs Council in Luxembourg. The Directive will introduce new EU-wide rules to protect whistleblowers who report breaches of EU law. “EU law breaches” include, amongst others, those relating to EU laws on product safety and compliance, Read More

The Nagoya Protocol five years into play: key points of attention when working with genetic resources

Tine Carmeliet

Genetic material from plants, animals, microbials or other biological origin is today frequently used not only by companies active in the pharmaceutical or plant breeding industry, but also by businesses in the cosmetics and food industries. Think of a German cosmetics company developing a cream based on a plant extract from Indonesia, or a dairy Read More

Netherlands: Debate between Dutch Minister of Care and pharmaceutical companies

Lars Braams

On 27 August 2019, the Dutch Minister of Care wrote an open letter in one of the main Dutch newspapers (De Volkskrant), addressed to pharmaceutical companies. In the letter he requested price transparency. He stated that when an explanation for a price increase is proposed by a pharmaceutical company (for example, high development costs or Read More

Germany Improves Patients’ Access to Medical Cannabis

Eda Zhuleku

The new Law for More Safety in the Supply of Pharmaceuticals in Germany (Gesetz für mehr Sicherheit in der Arzneimittelversorgung- GSAV) which has been in force since 16 August amends the law regarding the prescription and sale of medical cannabis in Germany. Since 10 March 2017, it has been possible for medical cannabis to be prescribed Read More

Netherlands: Hospitals request three-year suspension of Dutch Competition Act

Hannah Smit

The Dutch Association of Hospitals (NVZ) has published a press release announcing that it has appealed for a three-year temporary suspension of the Dutch Competition Act in the healthcare sector, as various healthcare institutions have entered into arrangements to save on costs that may be in violation of the Act. For example, the institutions have Read More